Cite
HARVARD Citation
Yazici, Y. et al. (2020). Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis & rheumatology. 72 (10), pp. 1694-1706. [Online].